2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
04:30 p.m. - 06:00 p.m.
MCCNO - Hall C
This session are outstanding clinical trials in ET and PV. Suggested session title<br /><br /><span style="caret-color: #000000; color: #000000; font-family: Aptos, Aptos_EmbeddedFont, Aptos_MSFontService, Calibri, Helvetica, sans-serif; font-size: 14.666667px; font-style: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration: none; display: inline !important; float: none;">ET and PV: Moving Beyond Conventional Therapy</span>
Treatment Considerations, Drug Development, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Adverse Events, Biological Processes, Genomics, Hematopoiesis, Immune Mechanism, Clinical Practice (Health Services and Quality), Diseases, Bleeding and Clotting, Bleeding Disorders, Platelet Disorders, Thromboembolism, Thrombotic Disorders, VWD, Myeloid Malignancies, Chronic Myeloid Malignancies, Research, Translational Research, MDS, MPN, CMML, Clinical Research, Clinical Trials, Study Population, Human, Adult, Elderly, Young Adult
PAPER

1038 Pelabresib monotherapy in high-risk essential thrombocythemia after hydroxyurea resistance or intolerance: results from Arm 4 of the open-label, Phase 2 MANIFEST study

Andrea Patriarca, MD, PhD, Joseph Scandura, MD, PhD2, Steven Knapper, DM, FRCPath, MBBChir3, Claire Harrison, DM4, Raajit K. Rampal, MD, PhD5, Nikki Granacher, MD6, Timothy Devos, MD, PhD7, Adam Mead, MBBChir8, Stephen Oh, MD, PhD9, Jeanne Palmer, MD10, Lino L Teichmann, MD11, Monika Wroclawska, MD, MBA12, Grace Cleary13, Sadhvi Khanna14, Francesco Passamonti, MD15
1 AOU Maggiore della Carità and University of Eastern Piedmont, Novara, Italy
2 Weill Cornell Medicine, New York, New York, United States
3 Cardiff University School of Medicine, Cardiff, United Kingdom
4 Guy’s and St Thomas’ NHS Foundation Trust, London, United Kingdom
5 Memorial Sloan Kettering Cancer Center, New York, New York, United States
6 Ziekenhuis aan de Stroom (ZAS) Cadix, Antwerp, Belgium
7 Laboratory of Molecular Immunology (Rega Institute), KU Leuven, Leuven, Belgium, University Hospitals Leuven, Leuven, Belgium
8 University of Oxford, Oxford, United Kingdom
9 Washington University School of Medicine in St. Louis, Saint Louis, Missouri, United States
10 Mayo Clinic, Phoenix, Arizona, United States
11 University Hospital Bonn, Bonn, Germany
12 Novartis Pharma AG, Basel, Switzerland
13 Novartis Ireland Limited, Dublin, Ireland
14 Novartis Pharma S.A.S, Rueil-Malmaison, France
15 Università degli Studi di Milano, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy

Background

Essential thrombocythemia (ET) is a myeloproliferative neoplasm (MPN) characterized by clonal thrombocytosis, hemorrhagic and thrombotic events, and potential progression to myelofibrosis (MF) or acute myeloid leukemia (AML) (Tefferi & Barbui. Mayo Clin Proc. 2015). Hydroxyurea (HU) is the standard first-line therapy for high-risk ET; HU resistance/intolerance occurs in ~20% of patients (pts) and is associated with increased risk of disease transformation and poor survival (Park et al. Cancer Med. 2023). There is a significant unmet need for effective treatments for pts with HU resistance/intolerance (Harrison et al. Blood. 2017). Pelabresib (PELA), an oral, investigational bromodomain and extra-terminal domain inhibitor that epigenetically modulates dysregulated transcriptional and inflammatory pathways implicated in MPN biology, is in development for MF (Gomes & Harrison. Curr Hematol Malig Rep. 2023). Arm 4 of the 4-arm, open-label, Phase 2 MANIFEST study (NCT02158858) investigated the efficacy and safety of PELA monotherapy in pts with high-risk ET and resistance/intolerance to HU.

Methods

Key inclusion criteria for Arm 4 pts were: a diagnosis of ET, as per the 2016 World Health Organization criteria (Swerdlow et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 2017); high-risk disease; HU resistance/intolerance; life expectancy >24 weeks; platelets >600×10?/L; and ≥2 measurable symptoms using the MPN Symptom Assessment Form (Scherber et al. Blood. 2011). High-risk disease was defined by ≥1 of the following: age >60 years, platelets >1500×10?/L (any time during disease), previous thrombosis or ET-related hemorrhage, and diabetes or hypertension requiring treatment for >6 months. Pts received PELA 225 mg once daily for 14 days per 21-day cycle. The primary endpoint was complete hematologic response (CHR; platelets ≤400×10?/L and white blood cells ≤10×10?/L over 2 consecutive cycles, normal spleen size by palpation or imaging), as assessed by modified European LeukemiaNet criteria (Barosi et al. Blood. 2009). Secondary endpoints included partial hematologic response (PHR; platelets >400-600×10?/L, white blood cells ≤10×10?/L, over 2 consecutive cycles), overall hematologic response (OHR; complete or partial response), duration of hematologic response, ≥50% symptom improvement from baseline (TSS50), rate of treatment-emergent adverse events (TEAEs), and hemorrhagic and thromboembolic events. Transformation to AML was an exploratory endpoint.

Results

At the data cutoff (January 9, 2025), 21 pts were treated with PELA for a median duration of 107 weeks (range, 2-167). Baseline characteristics reflected a high-risk population, in line with eligibility criteria: median age 64 years and median platelet count 793×10?/L (range, 418-1777). Median total symptom score was 30.6 (range, 7-123); median duration of previous HU treatment was 101.7 months (range, 1-337) and 57.1% of pts (12/21) had received ≥2 prior therapies.

PELA demonstrated robust hematologic activity: 57.1% of pts (12/21) achieved CHR, including 33.3% (7/21) by Cycle 2; 38.1% of pts (8/21) achieved PHR; and 66.7% of pts (14/21) achieved OHR, with a median duration of 21.1 weeks. Rapid and sustained platelet reductions were observed, with a median reduction of -350.0×10?/L (range, -802 to 392) by Cycle 1, Day 14; this was sustained throughout the treatment period, with a median platelet reduction of -461.0×10?/L (range, -925 to -116) by Cycle 21, Day 1. TSS50 was achieved in 56.3% of evaluable pts (9/16).

Ten pts (47.6%; 10/21) had Grade (Gr) ≥3 TEAEs; nausea and decreased appetite were the most common (9.5% each; 2/21). Overall, 19.0% of pts (4/21) experienced a Gr 3 hemorrhagic event and one pt (4.8%; 1/21) experienced a Gr 3 thromboembolic event. All Gr 3 hemorrhagic or thromboembolic events resolved; there were no Gr 4 or 5 thromboembolic or hemorrhagic events. One pt (4.8%; 1/21) reported transformation to AML. No deaths were reported.

Conclusions

PELA monotherapy demonstrated deep and durable hematologic responses, with rapid and sustained platelet reductions, in pts with high-risk ET who were resistant/intolerant to HU. TEAEs were consistent with the known safety profile of PELA and were as expected in this high-risk, heavily pretreated pt population. These findings support the development of PELA as a potential therapeutic option for pts with ET, providing meaningful, hematologic benefit in a population with a high unmet need.
Andrea Patriarca, MD, PhD: Takeda - Honoraria; Bristol Myers Squibb - Honoraria; Alexion - Honoraria; Pfizer - Honoraria; Sanofi - Honoraria; Sobi - Honoraria; Novartis - Honoraria; Incyte - Honoraria; Sobi - Consultancy (Includes expert testimony); Sanofi - Consultancy (Includes expert testimony)